Goal Attainment Scaling for Peripheral Neuropathy

Overseen By Alice Ye, MD

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: M.D. Anderson Cancer Center

Disqualifiers: Cognitive impairment, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

Duration: 12 weeks

45 Participants Needed

Trial Summary

Do I have to stop taking my current medications for this trial?

The trial information does not specify whether you need to stop taking your current medications. It seems to focus on behavioral aspects rather than medication changes.

How is Goal Attainment Scaling treatment different for peripheral neuropathy?

Goal Attainment Scaling is unique because it focuses on setting personalized goals for patients and measuring their progress towards these goals, rather than using a one-size-fits-all approach. This method is more flexible and tailored to individual needs compared to standard treatments that may not consider personal objectives. ^{1 2 3 4 5}

What is the purpose of this trial?

A behavioral trial aimed at helping patients identify what matters most to them and is part of a larger effort to pivot from disease-oriented care to whole-person care.

Research Team

Alice Ye, MD

Principal Investigator

M.D. Anderson Cancer Center

Eligibility Criteria

This trial is for individuals experiencing peripheral neuropathy, which often causes numbness, tingling, or pain in the limbs. Participants should be interested in a personalized approach to manage their condition by setting and working towards their own health goals.

Inclusion Criteria

I haven't received cancer treatment recently or have been on a stable treatment for 3 months.

Access to smartphone and internet for participating in a technology-based intervention

Provision of signed and dated electronic informed consent form

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants engage in behavioral interventions aimed at identifying personal values and goals

12 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

• Goal Attainment Scaling

Trial Overview The intervention being studied is Goal Attainment Scaling (GAS), a method that helps patients set personal health-related goals and track their progress over time. The study focuses on shifting from traditional disease treatment to individualized patient care.

Participant Groups

Group I: No Goal Encouragement Experimental Treatment 1 Intervention

Eligible participants will be identified using electronic health record

Group II: Goal Encouragement Experimental Treatment 1 Intervention

Eligible participants will be identified using electronic health record

Who Is Running the Clinical Trial?

M.D. Anderson Cancer Center

Lead Sponsor

Trials

3,107

Recruited

1,813,000+

Findings from Research

The Overall Neuropathy Limitations Scale (ONLS) shows high inter-rater reliability and a strong correlation with established measures of disability and physical health, indicating it is a reliable tool for assessing peripheral neuropathy activities.

The ONLS demonstrates better content validity and less ceiling effect compared to the Overall Disability Sum Score (ODSS), making it potentially more effective for both clinical practice and research in evaluating neuropathy limitations.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale. Graham, RC., Hughes, RA.[2022]

References

1. Netherlands pubmed.ncbi.nlm.nih.gov

Development of a youth-report measure of DPN symptoms: Conceptualization and content validation. [2020]

2. England pubmed.ncbi.nlm.nih.gov

A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale. [2022]

3. Italy pubmed.ncbi.nlm.nih.gov

Determinants of improvement in functional abilities in peripheral neuropathy patients undergoing rehabilitation: the role of Berg Balance Scale items. [2023]

4. England pubmed.ncbi.nlm.nih.gov

Can neuropathic screening tools be used as outcome measures? [2019]

5. United States pubmed.ncbi.nlm.nih.gov

Development of a health-related quality of life measure for peripheral neuropathy. [2017]